Navigation Links
Vasogen's Research Published in European Journal of Neuroscience
Date:1/28/2008

continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relat
'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Researchers Pinpoint Best Treatment to Reduce Deadly USA300, MRSA Staph Infections
2. Researchers develop darkest manmade material
3. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
4. Quintiles to Open Clinical Research Office in Wilmington, NC
5. Irving Dark Named Vice President of Cytel Clinical Research Services
6. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
7. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
10. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
11. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Halozyme Therapeutics, Inc. ... Conference Call for the second quarter 2015 on Monday, ... Dr. Helen Torley , president and chief executive ... post-market, Halozyme will release financial results for the second ... live through the "Investors" section of Halozyme,s corporate website ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... is processed to get such derivatives as ethylbenzene, a precursor to styrene, used ... within the automotive industry for the production of tyres and other components. Thus, ...
(Date:8/3/2015)... E-QURE Corp. (OTCQB: EQUR), a ... Signal Therapy device ("BST Device"), a new and novel ... chronic wounds, today announced that the Company has signed ... specializing in medical devices, for the marketing and distribution ... 70 years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... pumps to its comprehensive line of analytical laboratory equipment. With optimized features, such ... pumps provide a chemically resistant and maintenance-free solution for a broad range of ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2
... Madison, Wis. -- Rita Colwell, former director of ... Pollution and Human Health" at 5:30 p.m. Monday, Oct. ... of Wisconsin-Madison's Memorial Union. , ,Colwell headed the NSF ... Inc., and is a distinguished professor at the University ...
... Wis. -- Three Wisconsin businesses will receive funding ... Commerce Technology Assistance Grant (TAG) and Technology Venture Fund ... , SonoPlot, Inc. is a Madison company established in ... $100,000 TVF loan to purchase equipment and develop a ...
... help of new silicon-based compounds, scientists - and patients ... the tiny lithium batteries used in implantable devices to ... lithium battery is the workhorse of implantable devices, which ... the central nervous system make critical connections in, for ...
Cached Biology Technology:New battery technology helps stimulate nerves 2New battery technology helps stimulate nerves 3
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... $5 million National Science Foundation (NSF) grant to upgrade ... Owens Valley Solar Array (OVSA) http://www.ovsa.njit.edu/ ... is expected to help scientists better understand the nature ... the military. "Space weather incidents such as ...
... What:,Based on what we know about smoking, diet, ... estimate we could prevent approximately half of all ... Association for Cancer Research will host its Ninth ... Research at the Pennsylvania Convention Center, located in ...
... Bad Hofgastein, 6 October 2010 -- European patients are in ... medically assisted reproduction (MAR) treatment, experts from the European Society ... European Health Forum Gastein (EHFG). The EHFG is ... EU. This year it has attracted about 600 decision-makers from ...
Cached Biology News:$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Reproductive health: Checkerboard of infertility treatment in Europe 2Reproductive health: Checkerboard of infertility treatment in Europe 3
5-bromo-2'-deoxyuridine (BrdU) Cell Biology Cell Proliferation Bromodeoxyuridine (BrdU) and Related Products...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
... J. Karn (1995) This volume ... and methods for the study of major ... reverse transcriptase, ribonuclease H, integrase and protease. ... binding assays; Tat and Rev assays; HIV/CD4 ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: